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Chronic myeloid leukemia (CML) is a myeloproliferative 
disease that is characterized by the proliferation of myeloid cells
and their ability to preserve differentiation. Adenocarcinoma of
the stomach is a tumor type commonly seen within the fifth and
seventh decades. Secondary solid organ malignancies may
develop during chronic leukemias. Although this association is
commonly seen in chronic lymphocytic leukemia, a secondary
tumor may also develop during CML [1, 2]. Chronic myeloid cell
leukemia associated with signet-ring type adenocarcinoma of
the stomach is rarely seen. Seventeen cases of CML associated
with signet-ring adenocarcinoma of the stomach were 
previously reported in the literature (8 cases in Japan and 9
cases in Europe and the USA) [3, 4].
We report a case of CML associated with signet ring 
adenocarcinoma of the stomach. We emphasize that a 
malignancy might develop during CML, especially in the 
gastrointestinal system, with non-specific symptoms such as
weight loss and nausea.
A 47-year-old male patient with no complaints in his history
was admitted to our hospital with the complaints of malaise and
perspiration. He did not have any specific finding in his medical
history. His medical examination did not show any pathological
finding except conjunctival pallor. Laboratory findings were as
follows: erythrocyte sedimentation rate 90 mm/hour, 
hemoglobin 9.2 g/dl, hematocrit 26%, MCV 90 fl, leukocyte
170x109/L (neutrophil 80%) and thrombocyte 310x109/L. Six
percent blast cells were counted on blood smear, so bone 
marrow biopsy and aspiration were performed. Differential cell
count showed 8% blast cells, 2% eosinophils, 12% basophils,
and included hypercellular bone marrow and slightly increased
reticulin fibrils, and granulocytic hyperplasia with predominantly
increased young cells. Biochemical findings were found normal
except for the increased LDH finding. BCR-ABL fusion gene,
which was determined by reverse transcriptase polymerase
chain reaction (RT-PCR) method, was found positive.
Philadelphia chromosome was found as 85% in bone marrow
sample. He was diagnosed as CML and hydroxyurea 2 g/day
and interferon α 2b (6 million units) were started. All drugs were
stopped because of development of thrombocytopenia during
interferon therapy, and imatinib mesylate was started as 400
mg/day. He obtained hematologic remission in the 3rd month of
this therapy and Philadelphia chromosome was found negative
in bone marrow biopsy. BCR-ABL fusion gene could not be
found in the 6th month of therapy by the RT-PCR method. He
has maintained hematological and cytogenetic remission for
three years with imatinib mesylate therapy.
He had complaints of nausea and vomiting, early loss of
appetite during meals and weight loss of 5 kg within the next six
months. His laboratory findings were as follows: erythrocyte 
sedimentation rate 24 mm/hour, CRP 85 mg/l, hemoglobin 14
g/dl, hematocrit 42%, leukocyte 12x109/L (neutrophils
8.8x109/L) and thrombocyte 400x109/L; biochemical findingswere normal. Endoscopic examination was planned to investi-
gate clinical and laboratory findings. Upper gastrointestinal
endoscopy revealed a patchy ulcerated and erose solid tumor
almost obstructing the lumen on the proximal antrum. A biopsy
was taken and the pathological examination showed a slightly
differentiated adenocarcinoma that produced mucin and includ-
ed signet ring cell. Lymph node and liver metastasis were not
found by imaging methods and he was referred to the
Department of General Surgery.
Niitsu and colleagues [1] reported that stomach, breast and
esophageal cancers were commonly seen (in 8.3% out of 674
patients) in patients with a hematological malignancy. 
A secondary solid organ malignancy may develop during 
hematological malignancy such as CML. Any patient with cancer
usually has increased risk of development of a secondary 
cancer [5]. Moertel and colleagues [2] found 11 cases (2.1%) of
malignancy-associated malignancy in 528 cases of CML in a 
10-year period in the Mayo Clinic. They showed that leukemia
increased the cancer occurrence rate. Another study conducted
recently on this issue in Johns Hopkins Hospital revealed 14
cases (14%) of associated cancer in 90 CML patients in a 
10-year period and the majority of patients were older than 30
years. Their report included only one case of stomach 
adenocarcinoma. Carruth and colleagues [3] reported an 
18-year-old male who had Philadelphia chromosome-positive
CML associated with stomach adenocarcinoma.
Fujii [6] reported a 46-year-old female with Philadelphia 
chromosome-positive CML associated with stomach 
adenocarcinoma and five cases of CML with stomach adeno-
carcinoma in Japan. In later years at least three other case
reports were presented in the Japanese literature [7-9].
The finding of positive Philadelphia chromosome is 
remarkable in this presented case and other case reports. The
presence of Philadelphia chromosome excludes the hypothesis
that CML is a paraneoplastic finding of stomach adeno cancer.
Pathogenesis of gastrointestinal malignancies might be 
attributed to the drugs used in CML therapy or the immune sys-
tem dysfunction caused by leukemia [10].
Our patient was treated with hydroxyurea and interferon α-
2b. Imatinib mesylate was started after a short time because of
the development of thrombocytopenia during interferon therapy.
He had used this therapy for three years. Although there are
some recent studies about imatinib mesylate with genitourinary
tumors in rats [11,12], preliminary analysis of the safety data
from clinical trials and adverse event reports do not support
these findings. While association of two different malignancies
usually does not negatively affect prognosis, each malignancy
should be treated specifically [10].
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